CGBIO (CEO Hyun-seung Yu), a specialist in bio-regenerative medicine, announced on the 20th that it participated in the Global Spine Congress 2024 (GSC 2024) held recently in Bangkok, Thailand, showcasing its main spinal implant and biologic products and presenting the latest techniques using Novosis in spinal fusion surgery.
GSC 2024 is an annual conference organized by AO Spine, an international academic research organization in the spine field, where leading spine experts from around the world gather to share insights. Regarded as a globally authoritative spine conference, it attracts about 2,000 spine surgeons from over 80 countries and features more than 100 sessions.
At the GSC 2024, CGBIO introduced key products from its S&B (Spine & Biologic) division, including Novosis, Excender, and CGDERM Spinkle. Additionally, through the global academic seminar ‘Meet the Master,’ CGBIO promoted the clinical effects of Novosis and established collaborative relationships with global spine specialists.
The ‘Meet the Master’ session, held on the third day of the event, focused on the theme “Unveiling the Latest Surgical Techniques on rhBMP-2 in Spinal Fusion.” Professor Jeffrey Wang from the Keck Medical Center of USC and Professor S. Tim Yoon from Emory University Hospital attended as session chairs, while Professor Samuel K. Cho from Mount Sinai Hospital, Professor Lee Han-dong from Ajou University Hospital’s Orthopedic Department, and Dr. Park Cheol-wung, Director of Daejeon Woori Hospital, participated as speakers.
The presentations garnered significant attention and covered clinical experiences and techniques related to CGBIO’s spine products, including Novosis and Excender. Specific topics included ▲Novosis, the latest trend in bone biology ▲Safety and efficacy of Novosis Putty containing a small amount of rhBMP-2 in Oblique Lumbar Interbody Fusion (OLIF) ▲Early experience with Transforaminal Lumbar Interbody Fusion (TLIF) using Excender and Novosis through Biportal Endoscopic Spine Surgery.
Professor Samuel K Cho, who opened the first session, introduced the latest trends in bone biology. He explained why Novosis is the optimal bone substitute for spinal fusion surgery. Novosis applies a ceramic material carrier that effectively releases bone morphogenetic protein, demonstrating excellent bone formation ability with a low dose of bone morphogenetic protein while reducing the risk of adverse reactions such as bone formation in unwanted areas.
Professor Lee Han-dong shared preliminary clinical results of ‘Novosis Putty,’ a next-generation bone substitute applied in Oblique Lumbar Interbody Fusion (OLIF). He evaluated the bone fusion effect of Novosis Putty more favorably compared to the fusion rates of DBM (Demineralized Bone Matrix) or autologous bone, which are reported to show a 95% fusion rate in the existing literature.
Dr. Park Cheol-wung introduced the advantages of Excender, a height-expandable cage optimized for minimally invasive surgery in Biportal Endoscopic Spine Surgery. He also shared encouraging clinical results of Novosis Putty, which enables early ambulation based on high bone fusion results, improves pain management, and reduces complication rates.
CGBIO reported that through these presentations, they confirmed the keen interest of global medical professionals in Novosis and Novosis Putty and verified the high innovation of the products, with some proposing participation in upcoming clinical trials for Novosis Putty in the United States.
Furthermore, CGBIO operated a joint booth with Innosys throughout the conference, seeking new business opportunities and discovering new agents in Asian countries. CGBIO prominently showcased the excellence of its products, focusing on ▲bone substitute ‘NOVOSIS’ ▲height-expandable cage ‘Excender’ ▲minimally invasive screw ‘Colonnade’ ▲anti-adhesion agent ‘CGDERM Spinkle’.
Innosys promoted the functions of its products, led by ‘L’DISQ,’ the world’s first spinal pain treatment device capable of directional control using microelectrodes, along with ▲’Unispace’ (3D printing cervical cage), a Posterior Cervical Fusion Implant ▲’Innoverse screw’ for spinal fixation, scheduled for release this year ▲’Expedio balloon catheter’ for treating spinal stenosis.
Hyun-seung Yu, CEO of CGBIO, stated, “It was a meaningful opportunity to effectively introduce CGBIO’s innovative solution products to the global market, and to discuss academic insights for building consensus on the clinical effects of Novosis and mutual development. We will continue to seek opportunities to expand our global network, establish long-term collaborative relationships, and strengthen our position in the global market by expanding our potential customer base, including existing Key Opinion Leaders (KOLs).”
▲ Global medical professionals attending CGBIO’s global academic seminar ‘Meet the Master’ at GSC 2024 (Image 1)
▲ Global medical professionals attending CGBIO’s global academic seminar ‘Meet the Master’ at GSC 2024 (Image 2)
